English | Español
Patient Daily | Feb 6, 2026

Lilly reports strong Q4 results as Mounjaro and Zepbound drive revenue growth
Patient Daily | Feb 6, 2026

Pfizer releases early Metsera obesity drug data; FDA decisions expected on key therapies
Patient Daily | Feb 6, 2026

Amgen highlights extended dosing potential for obesity drug MariTide
Patient Daily | Feb 6, 2026

Amgen declines FDA request to withdraw rare disease drug Tavneos
Patient Daily | Feb 6, 2026

Novartis maintains acquisition focus while reporting strong financial results
Patient Daily | Feb 6, 2026

GSK focuses on complications from obesity rather than GLP-1 drugs
Patient Daily | Feb 6, 2026

Eli Lilly sees opportunity as Novo Nordisk's oral Wegovy expands obesity drug market
Patient Daily | Feb 6, 2026

Congressman questions transparency of FDA's priority voucher program

Trending
+ Pharmaceuticals
Patient Daily | Apr 5, 2026

Amplifon announces $2 billion acquisition of GN Hearing in strategic shift
Patient Daily | Apr 7, 2026

ProPublica examines impact of RFK Jr.'s vaccine policies on childhood disease risks
+ Regulatory
Patient Daily | Apr 9, 2026

Reason Foundation commentator on vaccine liability: 'Exposing vaccine makers to the machinations of trial lawyers will stymie the development of innovative vaccines'
+ Regulatory
Patient Daily | Apr 8, 2026

Columbia University Professor Masia on 340B: '340B has become a drug mark-up program. Hospitals buy drugs at low cost and sell them high'